UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Development and Validation of a Computational Model for Androgen Receptor Activity

Chemical research in toxicology, 2017-04, Vol.30 (4), p.946-964

2017

Volltextzugriff (PDF)

Molecules targeting the androgen receptor (AR) signaling axis beyond the AR‐Ligand binding domain

Medicinal research reviews, 2019-05, Vol.39 (3), p.910-960

2019

Volltextzugriff (PDF)

Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models

International journal of cancer, 2019-09, Vol.145 (5), p.1382-1394

2019

Volltextzugriff (PDF)

Topological dynamics of an intrinsically disordered N‐terminal domain of the human androgen receptor

Protein science, 2022-06, Vol.31 (6), p.e4334-n/a

2022

Volltextzugriff (PDF)

Orally Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer

Clinical cancer research, 2019-11, Vol.25 (22), p.6764-6780

2019

Volltextzugriff (PDF)

Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance

Proceedings of the National Academy of Sciences - PNAS, 2020-06, Vol.117 (22), p.12315-12323

2020

Volltextzugriff (PDF)

Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer

Journal of medicinal chemistry, 2019-01, Vol.62 (2), p.941-964

2019

Volltextzugriff (PDF)

Endocrine disrupting activities and immunomodulatory effects in lymphoblastoid cell lines of diclofenac, 4-hydroxydiclofenac and paracetamol

Toxicology letters, 2018-09, Vol.294, p.95-104

2018

Volltextzugriff (PDF)

Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201)

European urology, 2018-01, Vol.73 (1), p.4-8

2018

Volltextzugriff (PDF)

Androgen insensitivity syndrome

Baillière's best practice & research. Clinical endocrinology & metabolism, 2015-08, Vol.29 (4), p.569-580

2015

Volltextzugriff (PDF)

UHRF1 promotes androgen receptor-regulated CDC6 transcription and anti-androgen receptor drug resistance in prostate cancer through KDM4C-Mediated chromatin modifications

Cancer letters, 2021-11, Vol.520, p.172-183

2021

Volltextzugriff (PDF)

Development of Novel Inhibitors Targeting the D-Box of the DNA Binding Domain of Androgen Receptor

International journal of molecular sciences, 2021-03, Vol.22 (5), p.2493

2021

Volltextzugriff (PDF)

Structural Insights of Transcriptionally Active, Full-Length Androgen Receptor Coactivator Complexes

Molecular cell, 2020-09, Vol.79 (5), p.812-823.e4

2020

Volltextzugriff (PDF)

Discovery of A031 as effective proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader for the treatment of prostate cancer

European journal of medicinal chemistry, 2021-04, Vol.216, p.113307, Article 113307

2021

Volltextzugriff (PDF)

H3K9 methylation drives resistance to androgen receptor-antagonist therapy in prostate cancer

Proceedings of the National Academy of Sciences - PNAS, 2022-05, Vol.119 (21), p.e2114324119

2022

Volltextzugriff (PDF)

Androgen action and metabolism in prostate cancer

Molecular and cellular endocrinology, 2012-09, Vol.360 (1-2), p.3-13

2012

Volltextzugriff (PDF)

An androgen receptor N-terminal domain antagonist for treating prostate cancer

The Journal of clinical investigation, 2013-07, Vol.123 (7), p.2948-2960

2013

Volltextzugriff (PDF)

Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands

Journal of medicinal chemistry, 2019-12, Vol.62 (24), p.11218-11231

2019

Volltextzugriff (PDF)

2,4-dienoyl-CoA reductase regulates lipid homeostasis in treatment-resistant prostate cancer

Nature communications, 2020-05, Vol.11 (1), p.2508-17, Article 2508

2020

Volltextzugriff (PDF)

Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer

Journal of medicinal chemistry, 2021-09, Vol.64 (17), p.12831-12854

2021

Volltextzugriff (PDF)

Advances in the understanding of androgen receptor structure and function and in the development of next-generation AR-targeted therapeutics

Steroids, 2024-10, Vol.210, p.109486, Article 109486

2024

Volltextzugriff (PDF)

Synthesis of curcumin derivatives targeting androgen receptor for castration‐resistant prostate cancer therapy

Chemical biology & drug design, 2024-07, Vol.104 (1), p.e14583-n/a

2024

Volltextzugriff (PDF)

Novel Selective Agents for the Degradation of Androgen Receptor Variants to Treat Castration-Resistant Prostate Cancer

Cancer research (Chicago, Ill.), 2017-11, Vol.77 (22), p.6282-6298

2017

Volltextzugriff (PDF)

Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis

Oncogene, 2014-05, Vol.33 (22), p.2815-2825

2014

Volltextzugriff (PDF)

The androgen receptor is a tumor suppressor in estrogen receptor–positive breast cancer

Nature medicine, 2021-02, Vol.27 (2), p.310-320

2021

Volltextzugriff (PDF)

1 – 25 von 22.964

Suche als RSS-Feed

Aktive Filter

KollektionMEDLINE

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(21.146)
Mit Volltextzugriff
(19.291)

Publikationsform

Sprache

15 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(19.900)
Life Sciences & Biomedicine
(18.747)
Humans
(17.023)
Male
(16.852)
Animals
(10.658)
Receptors, Androgen - Metabolism
(9.526)
Female
(7.141)
Receptors, Androgen - Genetics
(7.112)
Biological And Medical Sciences
(5.753)
Androgens
(5.386)
Androgen Receptor
(5.100)
Endocrinology & Metabolism
(4.820)
Prostate Cancer
(4.641)
Oncology
(4.308)
Mice
(3.869)
Medical Sciences
(3.823)
Cell Line, Tumor
(3.640)
Biochemistry & Molecular Biology
(3.479)
Androgen Receptors
(3.465)
Prostatic Neoplasms - Metabolism
(3.407)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

EZB Electronic Journals Library
(11.014)
Ingenta
(9.953)
Journals@Ovid
(8.437)
Elsevier ScienceDirect Journals Complete
(5.265)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(4.328)
Single Journals
(3.754)
Wiley Online Library Journals Frontfile Complete
(3.427)
IngentaConnect Journals
(3.378)
Wiley Online Library Full Collection 2018
(2.817)
Oxford Journals
(2.003)
SpringerLink Journals - AutoHoldings
(1.928)
Oxford Journals 2020 Medicine
(1.333)
Nature Journals Online
(1.244)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(1.184)
Nexis Uni
(689)
Taylor & Francis Journals
(641)
Taylor & Francis Current Content Access
(622)
Taylor & Francis:Master (3349 titles)
(500)
JSTOR
(412)

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(11)
... seit 90 Tagen
(77)

Menü

Weitere Dienste

Einstellungen

Development and Validation of a Computational Model for Androgen Receptor Activity

Molecules targeting the androgen receptor (AR) signaling axis beyond the AR‐Ligand binding domain

Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models

Topological dynamics of an intrinsically disordered N‐terminal domain of the human androgen receptor

Orally Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer

Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance

Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer

Endocrine disrupting activities and immunomodulatory effects in lymphoblastoid cell lines of diclofenac, 4-hydroxydiclofenac and paracetamol

Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201)

Androgen insensitivity syndrome

UHRF1 promotes androgen receptor-regulated CDC6 transcription and anti-androgen receptor drug resistance in prostate cancer through KDM4C-Mediated chromatin modifications

Development of Novel Inhibitors Targeting the D-Box of the DNA Binding Domain of Androgen Receptor

Structural Insights of Transcriptionally Active, Full-Length Androgen Receptor Coactivator Complexes

Discovery of A031 as effective proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader for the treatment of prostate cancer

H3K9 methylation drives resistance to androgen receptor-antagonist therapy in prostate cancer

Androgen action and metabolism in prostate cancer

An androgen receptor N-terminal domain antagonist for treating prostate cancer

Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands

2,4-dienoyl-CoA reductase regulates lipid homeostasis in treatment-resistant prostate cancer

Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer

Advances in the understanding of androgen receptor structure and function and in the development of next-generation AR-targeted therapeutics

Synthesis of curcumin derivatives targeting androgen receptor for castration‐resistant prostate cancer therapy

Novel Selective Agents for the Degradation of Androgen Receptor Variants to Treat Castration-Resistant Prostate Cancer

Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis

The androgen receptor is a tumor suppressor in estrogen receptor–positive breast cancer

Aktive Filter

Suchergebnisse filtern